These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9704720)

  • 1. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.
    Chouaid C; Bassinet L; Fuhrman C; Monnet I; Housset B
    J Clin Oncol; 1998 Aug; 16(8):2700-7. PubMed ID: 9704720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
    Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
    J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
    Chan KK; Siu E; Krahn MD; Imrie K; Alibhai SM
    J Clin Oncol; 2012 Apr; 30(10):1064-71. PubMed ID: 22393098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
    Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
    Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
    Calhoun EA; Schumock GT; McKoy JM; Pickard S; Fitzner KA; Heckinger EA; Powell EF; McCaffrey KR; Bennett CL
    Pharmacoeconomics; 2005; 23(8):767-75. PubMed ID: 16097839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial.
    Bojke L; Sculpher M; Stephens R; Qian W; Thatcher N; Girling D
    Pharmacoeconomics; 2006; 24(5):443-52. PubMed ID: 16706570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
    Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
    J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.
    Numnum TM; Kimball KJ; Rocconi RP; Kilgore LC; Straughn JM
    Int J Gynecol Cancer; 2007; 17(5):1019-24. PubMed ID: 17386043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
    Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
    Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.
    Cheung MC; Prica A; Graczyk J; Buckstein R; Chan KK
    Leuk Lymphoma; 2016 Aug; 57(8):1865-75. PubMed ID: 26758765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Younis T; Rayson D; Jovanovic S; Skedgel C
    Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.
    Eldar-Lissai A; Cosler LE; Culakova E; Lyman GH
    Value Health; 2008; 11(2):172-9. PubMed ID: 18380630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
    Barnes G; Pathak A; Schwartzberg L
    Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
    Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
    Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.